Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - May 22, 2019 - ISN-WCN 2019 - Mark Cooper, MD - Melbourne, Australia

ISN-WCN 2019 Mark Cooper addresses the role of SGLT2 inhibitors in patients with diabetic kidney disease with regard to effects on renal function.

Video navigation menu

Effect of SGLT2 inhibitors on eGFR in diabetes 00:23
SGLT2 inhibition in non-diabetic patients 03:52
Hemodynamic and non-hemodynamic effects of SGLT2-i 07:23
Renoprotective effects of SGLT2 inhibitors in diabetes 09:59
Trials with SGLT2 inhibitors in chronic kidney disease 11:13

Educational information

This lecture by Mark Cooper was part of a CME accredited symposium "SGLT2 inhibition in CKD: Discussing the key questions and evidence"

Faculty

Mark Cooper, MD - Inaugural Head of the Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

View slides of Mark Cooper View our meeting report

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.